BioCentury
ARTICLE | Company News

Intas launches biosimilar rituximab in India

May 10, 2013 1:12 AM UTC

Intas Pharmaceuticals Ltd. (Ahmedabad, India) launched Mabtas rituximab in India to treat non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) alone or in combination with chemotherapy. The product is a biosimilar of Rituxan rituximab, which Biogen Idec Inc. (NASDAQ:BIIB) and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) co-market in the U.S. Roche markets it as MabThera elsewhere. The chimeric mAb against CD20 antigen is approved in the EU and U.S. to treat NHL, CLL and rheumatoid arthritis (RA), and to treat diffuse large B cell lymphoma (DLBCL) in the EU. ...